Neuroendocrine tumours of the small bowel: Interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A

QJM: An International Journal of Medicine

Volumn 109, Issue 2, 2016, Pages 111-115

  Ardill, J E S ^a,b,c   Armstrong, L ^a   Smye, M ^b   Doherty, R ^b   Mccance, D R ^b,c   Johnston, B T ^b,c  

^a Regional Regulatory Peptide Laboratory   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CHROMOGRANIN A; NEUROKININ A; PROTON PUMP INHIBITOR; TUMOR MARKER;

5 HYDROXY INDOLE ACETIC ACID URINE LEVEL; ADULT; ARTICLE; ATROPHIC GASTRITIS; CANCER PATIENT; CANCER REGISTRY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; LABORATORY TEST; LIMIT OF QUANTITATION; LUNG NEUROENDOCRINE TUMOR; LUNG TUMOR; MAJOR CLINICAL STUDY; NEUROENDOCRINE TUMOR; NEUROENDOCRINE TUMOR OF THE SMALL BOWEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE; SMALL INTESTINE TUMOR; UNITED KINGDOM; URINE LEVEL; BLOOD; DIFFERENTIAL DIAGNOSIS; FEMALE; INTESTINAL NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; NORTHERN IRELAND; PATHOLOGY; REGISTER; REPRODUCIBILITY; SMALL INTESTINE; URINE;

ADULT; BIOMARKERS, TUMOR; CHROMOGRANIN A; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYDROXYINDOLEACETIC ACID; INTESTINAL NEOPLASMS; INTESTINE, SMALL; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; NEUROKININ A; NORTHERN IRELAND; REGISTRIES; REPRODUCIBILITY OF RESULTS;

EID: 84960103760     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcv095     Document Type: Article

References (18)

1. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, et al. Guidelines for the management of gastro-enteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2012; 61:6-32.
2. Modlin IM, Ö berg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008; 9:61-72.
3. Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003; 177:337-41.
4. Stridsberg M, Eriksson B, Oberg K, Janson ET. A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A. Regul Pept 2004; 117:219-27.
5. Manfé AZ, Norberto L, Marchesini M, Lumachi F. Usefulness of chromogranin A, neuron-specific enolase and 5-hydroxyindolacetic acid measurements in patients with malignant carcinoids. in vivo 2011; 25:1027-9.
6. Ardill JE, O'Dorisio TM. 2010 Circulating markers in neuroendocrine tumours of the enteropancreatic tract: application to diagnosis, monitoring disease and as prognostic indicators. Endocrinol Metab Clin North Am 2010; 39:777-90.
7. Deacon AC. The measurement of 5-hydroxyindole acetic acid in urine. Ann Clin Biochem 1994; 31:215-32.
8. Tellez MR, Mamikunian G, O'Dorisio TM, Vinik AI, Woltering EA. A single fasting plasma 5-HIAA value correlates with 24-h urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs). Pancreas 2013; 42:405-10.
9. Conlon JM, Deacon CF, Richter G, Schmidt WE, Stöckmann F, Creutzfeldt W. Measurement and partialcharacterization of the multiple forms of neurokinin A-like immunoreactivity in carcinoid tumours. Regul Pept 1986; 13:183-96.
10. Theodorsson-Norheim E, Norheim I, Ö berg K, Brodin E, Lundberg JM, Tatemoto K, et al. Neuropeptide K: a major tachykinin in plasma and tumor tissues from carcinoid patients. Biochem Biophys Res Commun 1985; 131:77-83.
11. Turner GB, Johnston BT, McCance DR, McGinty A, Watson RGP, Patterson CC, et al. Circulating Markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut 2006; 55:1586-91.
12. Cunningham JL, Janson ET, Agarwal S, Grimelius L, Stridsberg M. Tachykinins in endocrine tumors and the carcinoid syndrome Eur J Endocrinol 2008; 159:275-82.
13. Ardill JE. Gut hormones: peptide biomarkers for neuroendocrine tumours of the gastro-entero-pancreatic tract. Ann Clin Biochem 2008; 45:539-59.
14. Mamikunian P, Ardill JE, O'Dorisio TM, Krutzik, SR, Vinik AI, Go VLW, et al. 2011 Validation of neurokinin A (NKA) assay in the United States and Europe. Pancreas 2011; 40: 1000-5.
15. Rinke A, Mü ller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27:4656-63.
16. Welin S, StridsbergM, CunninghamJ, Granberg D, Skogseid B, Oberg K, et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 2009; 89:302-7.
17. Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012; 95:135-56.
18. Khan MS, El-Khouly F, Davies P, Toumpanakis C, Caplin ME. Long-term results of treatment of malignant carcinoid syndrome with prolonged release (Somatuline Autogel). Aliment Pharmacol Ther 2011; 34:235-42.